Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.52 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 7/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 2/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26264458 | 0.89 | SUCNR1 (0.66) | SUCNR1GPR132ABL1CTSLCTSS | |
| SCHEMBL26263274 | 0.86 | ALDH1A1 (0.64) | GPR132CTSLCTSSHPGDMAPK1 | |
| SCHEMBL26263263 | 0.83 | KAT6A (0.51) | GPR132CTSL | |
| SCHEMBL26263285 | 0.79 | SUCNR1 (0.81) | SUCNR1ABL1 | |
| SCHEMBL3745780 | 0.77 | AURKA (0.67) | ABL1SMN1; SMN2AURKATPX2 | |
| SCHEMBL31446549 | 0.77 | GPR132 (0.61) | GPR132ALDH1A1 | |
| SCHEMBL3995770 | 0.77 | FPR2 (0.63) | SUCNR1GPR132CTSSCTSKPPARG | |
| SCHEMBL26263250 | 0.76 | SUCNR1 (0.62) | SUCNR1KDM4E | |
| SCHEMBL25602455 | 0.76 | ABL1 (0.60) | ABL1BCRAURKATPX2 | |
| SCHEMBL26440578 | 0.75 | ALDH1A1 (0.66) | HPGDMAPK1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | SUCNR1 1/4885GPR132 433/4885ABL1 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.